Emd Serono Drug Patent Portfolio
Emd Serono owns 13 orange book drugs protected by 31 US patents with Luveris having the least patent protection, holding only 1 patent. And Tepmetko with maximum patent protection, holding 8 patents. Given below is the list of Emd Serono's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10849919 | Cladribine regimen for treating progressive forms of multiple sclerosis | 23 Nov, 2038 | Active |
| US8580781 | Pyridazinone derivatives | 19 Mar, 2030 | Active |
| US8329692 | Pyrimidinyl pyridazinone derivatives | 30 Oct, 2029 | Active |
| US8927540 | Pyridazinone derivatives | 21 Jul, 2028 | Active |
| US8658643 | Pyrimidinyl pyridazinone derivatives | 04 Jul, 2028 | Active |
| US9062029 | Pyrimidinyl pyridazinone derivatives | 04 Jul, 2028 | Active |
| US9403799 | Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase | 04 Jul, 2028 | Active |
| US8921357 | Pyridazinone derivatives | 30 May, 2028 | Active |
| US9284300 | Pyridazinone derivatives | 29 Apr, 2028 | Active |
| US7713947 | Cladribine regimen for treating multiple sclerosis | 16 Oct, 2026 | Active |
| US8377903 | Cladribine regimen for treating multiple sclerosis | 31 May, 2026 | Active |
| US7888328 | Oral formulations of cladribine | 11 Apr, 2024 | Expired |
| US8785415 | Oral formulations of cladribine | 11 Apr, 2024 | Expired |
| US7741268 | Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant | 02 Apr, 2024 | Expired |
| US7316997 | GH secretagogues and uses thereof | 14 Aug, 2023 | Expired |
| US8314066 | GH secretagogues and uses thereof | 14 Aug, 2023 | Expired |
| US8435945 | GH secretagogues and uses thereof | 14 Aug, 2023 | Expired |
| US6706681 | HCG liquid formulations | 16 Mar, 2021 | Expired |
| US7144577 | Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy | 14 Jul, 2020 | Expired |
| US7563763 | FSH and FSH variant formulations, products and methods | 23 Aug, 2019 | Expired |
| US7446090 | FSH formulation | 23 Aug, 2019 | Expired |
| US6319192 | Method for the treatment of fertility disorders | 23 Apr, 2019 | Expired |
| US6475521 | Biphasic controlled release delivery system for high solubility pharmaceuticals and method | 19 Mar, 2018 | Expired |
| US6660300 | Method of use of a biphasic controlled release delivery system for high solubility pharmaceuticals and method | 19 Mar, 2018 | Expired |
| US5898030 | hGH containing pharmaceutical compositions | 27 Apr, 2016 | Expired |
| US5767067 | Follicle stimulating hormone and pharmaceutical compositions containing same | 16 Jun, 2015 | Expired |
| US5767251 | Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof | 16 Jun, 2015 | Expired |
| US5861379 | Chimeric fatty body-pro-GRF analogs with increased biological potency | 26 May, 2015 | Expired |
| US6020311 | GRF analogs with increased biological potency | 26 May, 2015 | Expired |
| US6863891 | Oligopeptide lyophilisate, their preparation and use | 22 Feb, 2014 | Expired |
| US7605121 | Oligopeptide lyophilisate, their preparation and use | 22 Feb, 2014 | Expired |
Latest Legal Activities on Emd Serono's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Emd Serono.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Maintenance Fee Reminder Mailed
Critical
| 08 Jul, 2024 | US8314066 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 29 May, 2024 | US8329692 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 May, 2024 | US10849919 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Jan, 2024 | US9403799 |
|
Request for Trial Granted
Critical
| 20 Dec, 2023 | US7713947 |
| Mail-Petition Decision - Denied | 20 Dec, 2023 | US7713947 |
|
Request for Trial Granted
Critical
| 20 Dec, 2023 | US8377903 |
| Petition Decision - Denied | 19 Dec, 2023 | US7713947 |
| Petition Entered | 19 Dec, 2023 | US7713947 |
|
Request for Trial Granted
Critical
| 22 Sep, 2023 | US8377903 |
|
Request for Trial Granted
Critical
| 22 Sep, 2023 | US7713947 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Aug, 2023 | US9284300 |
| Termination or Final Written Decision | 16 Aug, 2023 | US10849919 |
|
Electronic Review
Critical
| 10 May, 2023 | US8377903 |
|
Electronic Review
Critical
| 05 May, 2023 | US8377903 |
Emd Serono's Drug Patent Litigations
Emd Serono's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jul 06, 2000, against patent number US6706681. The petitioner , challenged the validity of this patent, with SAMARITANI et al as the respondent. Click below to track the latest information on how companies are challenging Emd Serono's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7713947 | October, 2022 |
Final Written Decision - Appealed
(18 Dec, 2024)
| Merck Serono SA | TWi Pharmaceuticals, Inc. |
| US8377903 | October, 2022 |
Final Written Decision - Appealed
(18 Dec, 2024)
| Merck Serono SA | TWi Pharmaceuticals, Inc. |
| US7713947 | January, 2023 |
Final Written Decision - Appealed
(18 Sep, 2024)
| Merck Serono SA | Hopewell Pharma Ventures, Inc. et al. |
| US8377903 | January, 2023 |
Final Written Decision - Appealed
(18 Sep, 2024)
| Merck Serono SA | Hopewell Pharma Ventures, Inc. et al. |
| US7713947 | October, 2022 |
Trial Instituted
(20 Dec, 2023)
| Merck Serono SA | TWi Pharmaceuticals, Inc. |
| US8377903 | October, 2022 |
Trial Instituted
(20 Dec, 2023)
| Merck Serono SA | TWi Pharmaceuticals, Inc. |
| US7713947 | January, 2023 |
Trial Instituted
(22 Sep, 2023)
| Merck Serono SA | Hopewell Pharma Ventures, Inc. et al. |
| US8377903 | January, 2023 |
Trial Instituted
(22 Sep, 2023)
| Merck Serono SA | Hopewell Pharma Ventures, Inc. et al. |
| US10849919 | February, 2023 |
Terminated-Settled
(16 Aug, 2023)
| Ares Trading SA | Hopewell Pharma Ventures, Inc. et al. |
| US6706681 | July, 2000 |
Decision
(23 Jan, 2002)
| SAMARITANI et al | |
Emd Serono Drug Patents' Oppositions Filed in EPO
Emd Serono drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 16, 2018, by Generics (Uk) Ltd. This opposition was filed on patent number EP14001970A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP14001970A | Oct, 2018 | Generics (UK) Ltd | Granted and Under Opposition |
Emd Serono's Family Patents
Emd Serono Drug List
Given below is the complete list of Emd Serono's drugs and the patents protecting them.
1. Cetrotide
Cetrotide is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6319192 | Method for the treatment of fertility disorders |
23 Apr, 2019
(6 years ago)
| Expired |
| US6863891 | Oligopeptide lyophilisate, their preparation and use |
22 Feb, 2014
(11 years ago)
| Expired |
| US7605121 | Oligopeptide lyophilisate, their preparation and use |
22 Feb, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cetrotide's drug page
2. Egrifta
Egrifta is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7316997 | GH secretagogues and uses thereof |
14 Aug, 2023
(2 years ago)
| Expired |
| US8314066 | GH secretagogues and uses thereof |
14 Aug, 2023
(2 years ago)
| Expired |
| US8435945 | GH secretagogues and uses thereof |
14 Aug, 2023
(2 years ago)
| Expired |
| US7144577 | Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy |
14 Jul, 2020
(5 years ago)
| Expired |
| US5861379 | Chimeric fatty body-pro-GRF analogs with increased biological potency |
26 May, 2015
(10 years ago)
| Expired |
| US6020311 | GRF analogs with increased biological potency |
26 May, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Egrifta's drug page
3. Glucophage Xr
Glucophage Xr is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6475521 | Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
19 Mar, 2018
(7 years ago)
| Expired |
| US6660300 | Method of use of a biphasic controlled release delivery system for high solubility pharmaceuticals and method |
19 Mar, 2018
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Glucophage Xr's drug page
4. Gonal-f
Gonal-f is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7563763 | FSH and FSH variant formulations, products and methods |
23 Aug, 2019
(6 years ago)
| Expired |
| US5767067 | Follicle stimulating hormone and pharmaceutical compositions containing same |
16 Jun, 2015
(10 years ago)
| Expired |
| US5767251 | Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof |
16 Jun, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gonal-f's drug page
5. Gonal-f Rff
Gonal-f Rff is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5767067 | Follicle stimulating hormone and pharmaceutical compositions containing same |
16 Jun, 2015
(10 years ago)
| Expired |
| US5767251 | Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof |
16 Jun, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gonal-f Rff's drug page
Explore Our Curated Drug Screens
6. Gonal-f Rff Pen
Gonal-f Rff Pen is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7741268 | Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant |
02 Apr, 2024
(1 year, 9 months ago)
| Expired |
| US7446090 | FSH formulation |
23 Aug, 2019
(6 years ago)
| Expired |
| US5767067 | Follicle stimulating hormone and pharmaceutical compositions containing same |
16 Jun, 2015
(10 years ago)
| Expired |
| US5767251 | Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof |
16 Jun, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gonal-f Rff Pen's drug page
7. Luveris
Luveris is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5767251 | Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof |
16 Jun, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Luveris's drug page
8. Mavenclad
Mavenclad is protected by 5 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10849919 | Cladribine regimen for treating progressive forms of multiple sclerosis |
23 Nov, 2038
(12 years from now)
| Active |
| US7713947 | Cladribine regimen for treating multiple sclerosis |
16 Oct, 2026
(8 months from now)
| Active |
| US8377903 | Cladribine regimen for treating multiple sclerosis |
31 May, 2026
(4 months from now)
| Active |
| US7888328 | Oral formulations of cladribine |
11 Apr, 2024
(1 year, 9 months ago)
| Expired |
| US8785415 | Oral formulations of cladribine |
11 Apr, 2024
(1 year, 9 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mavenclad's drug page
9. Ovidrel
Ovidrel is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6706681 | HCG liquid formulations |
16 Mar, 2021
(4 years ago)
| Expired |
| US5767251 | Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof |
16 Jun, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ovidrel's drug page
10. Saizen
Saizen is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5898030 | hGH containing pharmaceutical compositions |
27 Apr, 2016
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Saizen's drug page
11. Serostim
Serostim is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5898030 | hGH containing pharmaceutical compositions |
27 Apr, 2016
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Serostim's drug page
12. Tepmetko
Tepmetko is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8580781 | Pyridazinone derivatives |
19 Mar, 2030
(4 years from now)
| Active |
| US8329692 | Pyrimidinyl pyridazinone derivatives |
30 Oct, 2029
(3 years from now)
| Active |
| US8927540 | Pyridazinone derivatives |
21 Jul, 2028
(2 years from now)
| Active |
| US8658643 | Pyrimidinyl pyridazinone derivatives |
04 Jul, 2028
(2 years from now)
| Active |
| US9062029 | Pyrimidinyl pyridazinone derivatives |
04 Jul, 2028
(2 years from now)
| Active |
| US9403799 | Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase |
04 Jul, 2028
(2 years from now)
| Active |
| US8921357 | Pyridazinone derivatives |
30 May, 2028
(2 years from now)
| Active |
| US9284300 | Pyridazinone derivatives |
29 Apr, 2028
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tepmetko's drug page
13. Zorbtive
Zorbtive is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5898030 | hGH containing pharmaceutical compositions |
27 Apr, 2016
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zorbtive's drug page